Trifarotene: A Novel Therapeutic Option for Acne

Table 1

Important clinical trials of trifarotene

Drug(s)	Location(s)	Indication	Phase	Identifier	Sponsor	Status
Trifarotene cream vs vehicle cream	France, Germany, Spain	Lamellar ichthyosis	II	NCT03738800; EudraCT 2018-003272-12; 18-ICH-001	Mayne Pharma International Ltd.	Ongoing
Trifarotene cream	USA	Early cutaneous T-cell lymphoma	I	NCT01804335; 2012–0710; NCI-2014-01377	MD Anderson Centre; Galderma R&D	Completed
Trifarotene cream vs vehicle cream and tazarotene	USA	Acne vulgaris	II	NCT01616654; RD.06. SPR18223	Galderma R&D	Completed
Trifarotene cream	USA	Acne vulgaris	III	NCT03915860; RD.06. SPR.118295	Galderma R&D	Ongoing
Trifarotene cream	Multinational	Acne vulgaris	III	NCT02189629; EudraCT 2014-001755-23	Galderma R&D	Completed
Trifarotene cream vs vehicle cream	Multinational	Acne vulgaris	III	PERFECT 2; NCT02556788; EudraCT 2016-002540- 13	Galderma R&D	Completed
Trifarotene cream vs vehicle cream	Multinational	Acne vulgaris	III	PERFECT 1; NCT025566369; EudraCT 2016-002860- 15	Galderma Research and Development (R&D)	Completed